Peptide Initiative

Peptide Mythbuster · Myth #003

FDA BANNED PEPTIDES FOR SAFETY

Following the money behind regulatory decisions

Verdict: BUSTED

01 / The claim

What people say

The FDA removed peptides from compounding because they're dangerous and were harming people — it was a public health decision, plain and simple.Regulatory trust assumption

02 / Evidence

The data

Each point of evidence assessed against the original claim.

Refutes

No Safety Signal

FDA cited lack of data, not adverse events. No documented safety crisis triggered the removals.

Refutes

Suspicious Timing

Ban finalized weeks before Eli Lilly's tirzepatide approval. Compounded versions cost 80-90% less.

Refutes

Active Litigation

Outsourcing Facilities Association and compounding pharmacies have filed federal lawsuits challenging the decision.

Refutes

Pharma Lobbying

Brand-name manufacturers spent $374 million lobbying Congress in 2023. Compounding pharmacies spent under $2 million.

Refutes

Historical Pattern

Similar removals preceded other branded drug launches. Pattern suggests market clearing, not safety enforcement.

Supports

Some Valid Concerns

Compounding quality does vary. Sterility and dosing consistency are legitimate regulatory interests.

Neutral

Data Gap Reality

Many peptides lack large-scale trials. Absence of safety data isn't proof of safety.

03 / Verdict

The ruling

BUSTED

No safety crisis preceded the ban. Timing suggests market protection for newly-approved branded drugs, not consumer safety.

04 / Key facts

The science

  1. 01ZERO DEATHSNo fatalities or serious adverse events from compounded peptides were cited in the FDA's removal justification.
  2. 02$1,060 VS $50Monthly cost of branded tirzepatide versus compounded versions. The price gap explains the lobbying intensity.
  3. 0317 PEPTIDESNumber of compounds removed from the 503A bulk list in a single regulatory action — unprecedented scope.
  4. 04FEDERAL LAWSUITSMultiple legal challenges argue the FDA violated administrative procedure and acted arbitrarily.

05 / Deep dive

Why it matters

The FDA removed 17 peptides from the 503A bulking list in late 2023, citing insufficient safety data — not documented harm. This happened weeks before tirzepatide (Zepbound) hit the market at $1,060/month. Multiple lawsuits now challenge the decision, arguing the real motive was eliminating cheaper compounded competition.

06 / Sources

References

  1. Drug Wars: How Big Pharma Raises Prices and Keeps Generics off the MarketFeldman, R. & Frondorf, E. (2017). Cambridge University Press.
  2. Product Hopping: A New FrameworkCarrier, M.A. & Shadowen, S.D. (2016). Notre Dame Law Review. View source
  3. Bulk Drug Substances Used in Compounding Under Section 503AFDA Center for Drug Evaluation (2023). Federal Register. View source
  4. OFA v. FDA: Complaint for Declaratory and Injunctive ReliefOutsourcing Facilities Association (2024). U.S. District Court.
  5. Comparing Generic Drug Markets in Europe and the United StatesWouters, O.J., Kanavos, P.G. & McKee, M. (2017). Milbank Quarterly. View source
  • regulation
  • compounding
  • tirzepatide
  • FDA
  • market-access

Peptide Mythbuster. Evidence-based analysis.